相关实验视频

Updated: Jun 27, 2025

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

LKB1 防止了 ILC2 的耗尽,以增强抗瘤免疫力

Hongshen Niu¹, Huasheng Zhang¹, Dongdi Wang¹

¹Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Department of Immunology and Microbiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

|April 26, 2024

概括

肝激酶B1 (LKB1) 抑制了2组先天性淋巴细胞 (ILC2) 中的疲状态. LKB1缺乏通过增加ILC2s上的PD-1表达来促进肺黑色素瘤转移.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
细胞生物学细胞生物学

背景情况:

第二组先天性淋巴细胞 (ILC2s) 是过敏炎症和瘤免疫的关键参与者.
瘤抑制剂肝激酶B1 (LKB1) 的突变与各种人类癌症有关,但其在ILC2s中的作用尚不清楚.

研究的目的:

研究LKB1在ILC2s中的功能及其对ILC2-介导瘤免疫力的影响.
阐明LKB1在癌症背景下影响ILC2功能的机制.

主要方法:

在ILC2s.中LKB1的条件消去.
对ILC2表型的分析,包括像PD-1这样的疲劳标志物.
在体内评估肺黑色素瘤转移.
研究激活T细胞 (NFAT) 途径的核因子.

主要成果:

在ILC2s中LKB1缺陷导致一种疲的表型.
缺乏LKB1的ILC2s通过NFAT通路激活来增加编程细胞死亡蛋白-1 (PD-1) 的表达.
废除LKB1促进了肺黑色素瘤的转移.
阻断PD-1恢复ILC2效应器功能,并增强体内抗瘤免疫力.

结论:

LKB1充当一个关键的调节器,防止ILC2耗尽.
通过促进ILC2的耗尽和PD-1的上调调节,LKB1缺乏会损害抗瘤免疫力.
准PD-1可以逆转LKB1驱动的ILC2功能障碍,并增强抗黑色素瘤反应.

关键词:

CP: 癌症癌症癌症 CP: 免疫学免疫学抗瘤免疫力抗瘤免疫力疲疲疲疲疲第2组是先天性淋巴细胞.肝激酶 B1 的作用.

更多相关视频

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...